ITCH20120008A1 - Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate - Google Patents

Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate Download PDF

Info

Publication number
ITCH20120008A1
ITCH20120008A1 IT000008A ITCH20120008A ITCH20120008A1 IT CH20120008 A1 ITCH20120008 A1 IT CH20120008A1 IT 000008 A IT000008 A IT 000008A IT CH20120008 A ITCH20120008 A IT CH20120008A IT CH20120008 A1 ITCH20120008 A1 IT CH20120008A1
Authority
IT
Italy
Prior art keywords
trop
akt
seq
cells
silencing
Prior art date
Application number
IT000008A
Other languages
English (en)
Italian (it)
Inventor
Saverio Alberti
Emanuela Guerra
Original Assignee
Saverio Alberti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saverio Alberti filed Critical Saverio Alberti
Priority to IT000008A priority Critical patent/ITCH20120008A1/it
Priority to AU2013261018A priority patent/AU2013261018A1/en
Priority to US14/401,456 priority patent/US20210311061A1/en
Priority to JP2015512199A priority patent/JP2015524051A/ja
Priority to IN10081DEN2014 priority patent/IN2014DN10081A/en
Priority to PCT/IT2013/000139 priority patent/WO2013171777A2/en
Priority to CN201380025540.9A priority patent/CN104395754A/zh
Priority to EP13739819.4A priority patent/EP2850433B1/en
Priority to CA2873017A priority patent/CA2873017A1/en
Publication of ITCH20120008A1 publication Critical patent/ITCH20120008A1/it

Links

Classifications

    • G01N33/57575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
IT000008A 2012-05-16 2012-05-16 Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate ITCH20120008A1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT000008A ITCH20120008A1 (it) 2012-05-16 2012-05-16 Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate
AU2013261018A AU2013261018A1 (en) 2012-05-16 2013-05-16 Use of Trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of CD9, Akt and molecules of the tetraspanin signalling network
US14/401,456 US20210311061A1 (en) 2012-05-16 2013-05-16 Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network
JP2015512199A JP2015524051A (ja) 2012-05-16 2013-05-16 ＣＤ９、Ａｋｔおよびテトラスパニンシグナル伝達ネットワークの分子の阻害剤に基づく抗腫瘍療法に対する応答の予測マーカーとしてのＴｒｏｐ−２の使用
IN10081DEN2014 IN2014DN10081A (enExample) 2012-05-16 2013-05-16
PCT/IT2013/000139 WO2013171777A2 (en) 2012-05-16 2013-05-16 Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network
CN201380025540.9A CN104395754A (zh) 2012-05-16 2013-05-16 Trop-2作为对基于cd9、akt和四跨膜蛋白信号传导网络分子的抑制剂的抗肿瘤疗法的应答的预测性标记的用途
EP13739819.4A EP2850433B1 (en) 2012-05-16 2013-05-16 Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of akt
CA2873017A CA2873017A1 (en) 2012-05-16 2013-05-16 Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000008A ITCH20120008A1 (it) 2012-05-16 2012-05-16 Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate

Publications (1)

Publication Number Publication Date
ITCH20120008A1 true ITCH20120008A1 (it) 2013-11-17

Family

ID=46832698

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000008A ITCH20120008A1 (it) 2012-05-16 2012-05-16 Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate

Country Status (9)

Country Link
US (1) US20210311061A1 (enExample)
EP (1) EP2850433B1 (enExample)
JP (1) JP2015524051A (enExample)
CN (1) CN104395754A (enExample)
AU (1) AU2013261018A1 (enExample)
CA (1) CA2873017A1 (enExample)
IN (1) IN2014DN10081A (enExample)
IT (1) ITCH20120008A1 (enExample)
WO (1) WO2013171777A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106467914A (zh) * 2015-08-18 2017-03-01 华东理工大学 靶向人TSPAN8基因的siRNA及其应用
ITUB20155701A1 (it) 2015-11-19 2017-05-19 Saverio Alberti Uso di Trop-2 circolante sierico come nuovo biomarcatore tumorale
KR101806294B1 (ko) * 2016-03-22 2017-12-07 주식회사 대웅제약 고형암 환자의 항암제 치료 반응성 예측용 마커
US12523663B2 (en) * 2019-06-04 2026-01-13 Inserm (Institut National De La Santé Et De La Rescherche Médicale) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
IL315662A (en) * 2022-03-16 2024-11-01 Astrazeneca Uk Ltd A scoring method for an anti trop2 antibody drug conjugate therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2798778A1 (en) * 2010-05-17 2011-11-24 Livtech, Inc. Anti-human trop-2 antibody having anti-tumor activity in vivo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP2393512B1 (en) * 2009-02-05 2016-10-26 ONCOXX Biotech s.r.l. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
JP2013510180A (ja) * 2009-11-06 2013-03-21 インフィニティ ファーマスーティカルズ、インク． ヘッジホッグ経路阻害剤の経口製剤
WO2011085276A2 (en) * 2010-01-09 2011-07-14 The Translational Genomics Research Institute Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
MX2012011887A (es) * 2010-04-16 2012-11-30 Genentech Inc Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2798778A1 (en) * 2010-05-17 2011-11-24 Livtech, Inc. Anti-human trop-2 antibody having anti-tumor activity in vivo

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HUAYI HUANG ET AL: "Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 12, 15 June 2005 (2005-06-15), pages 4357 - 4364, XP008128315, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-04-2107 *
NAKASHIMA KAZUE ET AL: "Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 20 DEC 2004, vol. 112, no. 6, 20 December 2004 (2004-12-20), pages 1029 - 1035, XP002694347, ISSN: 0020-7136 *
RAJI RHODA ET AL: "Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2011, vol. 30, 2011, pages 106, XP055052404, ISSN: 1756-9966 *
TREROTOLA M ET AL: "Upregulation of Trop-2 quantitatively stimulates human cancer growth.", ONCOGENE 10 JAN 2013, vol. 32, no. 2, 20 February 2012 (2012-02-20), pages 222 - 233, XP055057442, ISSN: 1476-5594 *
VARUGHESE JOYCE ET AL: "Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY DEC 2011, vol. 205, no. 6, December 2011 (2011-12-01), pages 567.e1 - 7, XP028116550, ISSN: 1097-6868 *
VARUGHESE JOYCE ET AL: "High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.", GYNECOLOGIC ONCOLOGY JUL 2011, vol. 122, no. 1, July 2011 (2011-07-01), pages 171 - 177, XP028221428, ISSN: 1095-6859 *
VARUGHESE JOYCE ET AL: "Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.", CANCER 15 JUL 2011, vol. 117, no. 14, 15 July 2011 (2011-07-15), pages 3163 - 3172, XP055057457, ISSN: 1097-0142 *

Also Published As

Publication number Publication date
EP2850433A2 (en) 2015-03-25
AU2013261018A1 (en) 2014-12-04
WO2013171777A3 (en) 2014-03-20
US20210311061A1 (en) 2021-10-07
IN2014DN10081A (enExample) 2015-08-21
WO2013171777A2 (en) 2013-11-21
CN104395754A (zh) 2015-03-04
EP2850433B1 (en) 2018-08-15
JP2015524051A (ja) 2015-08-20
CA2873017A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
Yu et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription
Tang et al. GPR116, an adhesion G-protein–coupled receptor, promotes breast cancer metastasis via the Gαq-p63RhoGEF-Rho GTPase pathway
Yagi et al. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells
Luo et al. TRAF6 regulates melanoma invasion and metastasis through ubiquitination of Basigin
Ma et al. Dual‐specificity tyrosine phosphorylation–regulated kinase 3 loss activates purine metabolism and promotes hepatocellular carcinoma progression
US20220267854A1 (en) Egfr and ros1 kinase in cancer
CN106148525B (zh) 肺癌中的ros激酶
Cheong et al. Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo
Liu et al. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy
IL200908A (en) Methods for classification of endometrial cancer and preparations for its treatment
Yao et al. Cyclin K interacts with β-catenin to induce Cyclin D1 expression and facilitates tumorigenesis and radioresistance in lung cancer
WO2011146945A2 (en) Alk and ros kinase in cancer
JP2010512730A (ja) 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ
ITCH20120008A1 (it) Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate
Nakamura et al. Overexpression of C16orf74 is involved in aggressive pancreatic cancers
Wang et al. FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression
Wilhelm et al. Troy is expressed in human stomach mucosa and a novel putative prognostic marker of intestinal type gastric cancer
CN101443022A (zh) 生长刺激蛋白质的用途
Osawa et al. The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells
US9233144B2 (en) Tyrosine kinase receptor TYRO3 as a therapeutic target in the treatment of cancer
Ding et al. Targeting lysosomal protease CTSL promotes anti-tumor immunity and sensitizes HNSCC to PD-1 blockade by stabilizing PDK1 and activating Akt–PD-L1 axis
IT202000031838A1 (it) Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici
US20120195916A1 (en) Method of treating cancer by inhibiting trim59 expression or activity
US20230357430A1 (en) Rnf167 and castor1 as novel mtor targets
US20240264161A1 (en) Biomarkers and uses thereof